Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Antihemophilic Factor Market size was over USD 3.22 billion in 2024 and is anticipated to cross USD 7.95 billion by 2037, growing at more than 7.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of antihemophilic factor is estimated at USD 3.42 billion.
The market is experiencing exponential growth due to the need for effective hemophilia treatments amidst high treatment costs. A 2021, study highlights that lifetime treatment costs for severe hemophilia B can reach up to USD 21 million for on-demand fix treatment and USD 23 million for preventive treatment. Research from 2022 further revealed that annual treatment costs between USD 150,000 and USD 300,000, excluding indirect costs like lost productivity. These staggering expenses underscore the demand for more efficient, cost-effective antihemophilic factors.
Factors believed to propel antihemophilic factor market growth include market evolution – trend adaptation, highlighting the importance of quickly adapting to market trends and consumer demands. Moreover, the value chain optimization and pricing strategy plays a crucial role as it enhance productivity and competitiveness & expansion respectively. Together, these elements set the stage for the market's sustained growth and leadership.
Antihemophilic Factor Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence and Underdiagnosis of Hemophilia: The global prevalence of hemophilia, affecting over 215,000 individuals, is a significant driver for the antihemophilic factor market. Emerging data suggest that the actual number could exceed 2 million due to underdiagnosis, highlighting a vast unmet need for effective treatments. Hemophilia predominantly affects those assigned males at birth, with those assigned females representing a smaller percentage of 18% of mild cases. This discrepancy underscores the conditions' complex diagnosis landscape, pushing for enhanced awareness and diagnostic capabilities, thereby driving demand for antihemophilic factors
- Advancements in Gene Therapy for Hemophilia B: The antihemophilic factor market is witnessing a transformative shift with the advent of gene therapy for hemophilia B. Clinical trials have shown promising results, with a dose-dependent expression of the factor IX (FIX) transgene yielding FIX activity levels of 2-11 IU/dL in participants. Remarkably, these therapeutic effects have demonstrated sustainability, with increased FIX activity in the range of 2-5% persisting for up to 8 years across various dose cohorts. This breakthrough underscores a potential paradigm shift in treatment methodologies, offering long-term benefits and reducing the dependency on traditional factor replacement therapies.
- Rising Demand in Healthcare: The increasing demand for antihemophilic factors in hospitals and clinics worldwide is a significant boosting factor for the sector. This rise in demand is attributed to the crucial role these factors play in treating hemophilia, a genetic disorder that impairs the blood’s ability to clot. As awareness and diagnosis of hemophilia improve globally, the need for effective treatments, including antihemophilic factors, escalates, thus boosting sectoral growth. This trend highlights the importance of these treatments in healthcare settings and underscores their impact on sectoral expansion.
Challenges
-
High Cost and Accessibility: The production and distribution of antihemophilic factors involve significant costs, making treatments expensive and less accessible to patients in lower-income regions.
- Navigating through rigorous regulatory processes for approval can be time-consuming and challenging, affecting the timely availability of treatments.
- With advancements in gene therapy and alternative treatments, there’s pressure on traditional antihemophilic factors products to innovate and remain competitive in the antihemophilic factor market.
Antihemophilic Factor Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.2% |
|
Base Year Market Size (2024) |
USD 3.22 billion |
|
Forecast Year Market Size (2037) |
USD 7.95 billion |
|
Regional Scope |
|
Antihemophilic Factor Segmentation
Product (Plasma Derived, VWF Complex, Recombinant Antihemophilic Factor)
The recombinant antihemophilic factor offering products such as recombinant in single-dose vials with 250 to 2000 international units, is estimated to hold 63% share of the global antihemophilic factor market by 2037. The vials, when reconstituted, include stabilizers like human albumin, calcium, and polyethylene glycol, contributing to the segment’s growth. The co-expression of Recombinant von Willebrand factor (rVWF) with human recombinant FVIII (rFVIII) containing no more than 2ng rVWF, having no significant effect on von Willebrand disease, thereby ensuring efficacy and safety. This technological sophistication is expected to bolster market dominance, particularly in regions with growing healthcare infrastructure and patient awareness.
Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The retail pharmacies segment in the antihemophilic factor market is poised to secure the largest revenue share of 57% by 2037. This dominance is largely due to the substantial patient engagement these outlets experience, which is expected to drive sales of leading antihemophilic factors such as NovoSeven and FEIBA, which have historically reached USD 2 billion and USD 800 million in sales respectively. The ultimate investments by manufacturers in targeted genetic mutation therapies contribute to the growth, fostering a robust pipeline of innovative products that bolster the segment's expansion.
Our in-depth analysis of the global antihemophilic factor market includes the following segments:
|
Type |
|
|
Product |
|
|
Distribution |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Antihemophilic Factor Industry - Regional Synopsis
North American Market Forecast
North America industry is predicted to account for largest revenue share of 53% by 2037, on account of robust healthcare system, substantial investment in research and development, and the presence of leading pharmaceutical companies in the region.The market growth in the region is expected on account of a robust healthcare system, substantial investment in research and development, and the presence of leading pharmaceutical companies focused on innovative therapies for hemophilia. The region’s strong regulatory frameworks and supportive policies for biologics and advanced drug therapies are contributing factors to its dominant position. Furthermore, the rapid growth of the over 65% population in the United States, with its increased adoption of medicare advantage, could account for this change, projecting an increase from 44% in 2021 to about 54% penetration in the medicare population by 2030. Additionally, the improved profitability of managed Medicaid, due to more coordinated and integrated care, is likely to further enhance the market growth prospects.
European Market Analysis
The Europe antihemophilic factor market is estimated to be the second largest, registering a share of about 24% by the end of 2037. The market’s growth is bolstered by high treatment-seeking rates, boosted by heightened awareness of hemophilia, well-established treatment protocols, and active patient organizations. Additionally, the region benefits from a sophisticated biotechnology sector and strategic partnerships between domestic and global pharmaceutical firms. Economic considerations also play a pivotal role, with the cost of severe hemophilia in five European countries reaching 2 billion in 2014, translating to nearly USD 300,000 per patient annually. With Germany bearing the highest per-patient costs at USD 300,000 and the UK, at the lower end at USD 200,000, the financial implications are vast and influence drug development and healthcare policy decisions across Europe’s diverse regions.
Companies Dominating the Antihemophilic Factor Landscape
- Genetech
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biogen Idec
- Bayer AG
- Octapharma
- Novo Nordisk
- Baxter
- Kedrion
- Pfizer Inc.
- Sanofi SA
- CSL Behring
Recent Developments
- Sanofi’s fitusiran, an innovative small interfering RNA (sIRNA) therapy, has successfully completed two phases 3 trials, demonstrating a significant decrease in annualized bleeding rates in hemophilia A or B patients, meeting its primary objective.
- Bayer AG has ceased the production of kogenate, a previously FDA-approved treatment for hemophilia A.
- Report ID: 5792
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Antihemophilic Factor Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
